rct
    2012
    High Quality

    Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial

    Fried MW, Navarro VJ, Afdhal N

    Published in JAMA

    Key Findings

    Higher-than-customary doses of oral silymarin did not significantly reduce serum ALT compared with placebo in chronic hepatitis C.

    Conclusions

    Well-powered null result for hepatitis C.

    Limitations

    Single disease population, ALT endpoint.

    Supplements Studied

    Higher-than-customary doses of silymarin did not significantly reduce serum ALT compared with placebo in chronic hepatitis C.

    Study Details

    Year:2012
    Sample Size:154
    Duration:24 weeks
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.